GMAB - Genmab A/S
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 39.16 |
| Open | 39.34 |
| Bid | 39.01 x 800 |
| Ask | 39.17 x 800 |
| Day's Range | 39.04 - 39.38 |
| 52 Week Range | 26.19 - 47.50 |
| Volume | |
| Avg. Volume | 419,673 |
| Market Cap | 25.548B |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | 33.75 |
| EPS (TTM) | 1.16 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.30 |
Fair Value
Related Research
GlobeNewswireGenmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, 11:20 AM PDT on June 13, 2023 (2:20 PM EDT / 8:20 PM CEST). A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology com
- GlobeNewswire
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 1, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Ge
Business WireGenmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
COPENHAGEN, Denmark, May 25, 2023--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.
- GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 23, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,098 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 5,408 shares at DKK 1,025.00,547 shares at DKK 1,032.00,125 shares at DKK 1,050.00,515 shares at DKK 1,136.00,3,503
ZacksAbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
BenzingaFDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epkinly is being co-developed and co-commercialized by Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) as part of the companies' oncology collaboration. Epkinly features a dual-targeted approach continuously binding to T-cells and CD20+ lymphoma B-cell
- Reuters
UPDATE 3-U.S. FDA approves Genmab-AbbVie's blood cancer therapy
The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The therapy, epcoritamab, which will be sold under the brand name Epkinly, treats a type of advanced large B-cell lymphoma, a cancer that starts in white blood cells. It is the first-of-its-kind therapy to be approved by the FDA for the disease which annually affects 150,000 people globally.
Business WireEPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark, May 19, 2023--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy. EPKINLY wa
- Investing.com
Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: new data from X4 Pharma, upcoming review dates for Krystal Biotech, and a torrent of news set for release at an annual biotech conference.
- GlobeNewswire
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Looking beyond this indication, together with our partner AbbVie Inc. (AbbVie), we are committed to a robust clinical development progr
- GlobeNewswire
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the award will be conducted by a single appeal arbitrator under the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration. The arbitration remains confidential, subject to t
- GlobeNewswire
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. The arbitral tribunal dismissed Genmab’s claims, on the basis that they should have been brought in the first arbitration. One of the three arbitrators dissented. Genmab has the right to seek review of the award, which it must do within a limited period of time. Genmab is c
- GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson we
ZacksStrength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investor's Business DailyGenmab Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Genmab stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 80 the day before. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
- GlobeNewswire
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapiesDiscovery programs against two differentiated targets are underway Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with appl
- GlobeNewswire
Completion of share buy-back program
Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 31, 2023. On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Unit program. The share buy-back program was expected to be completed no later than March 31, 2023, and to comprise up to 220,000 shares. The following transactions were executed under the program from
- GlobeNewswire
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 90,054 restricted stock units to members of management and employees of the Company and the Company’s subsidiaries and 16,276 warrants to the employees of the Compa
- GlobeNewswire
Passing of Genmab A/S’ Annual General Meeting
Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2023, the Annual Report for 2022 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2022 Compensation Report was approvedSix members of the Board of Directors were re-electedPricewaterhouseCoopers was re-elected as auditor of the CompanyThe proposals from the Board of Directors on the Board of Directors' remuneration for 2023, the propos
- GlobeNewswire
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
Media ReleaseCOPENHAGEN, Denmark; March 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that Martine van Vugt has been appointed to Chief Strategy Officer and promoted to Executive Vice President effective March 29, 2023. Martine will oversee Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. Martine joined Genmab in 2001 and most recently served as Genmab’s Senior Vice President, Corporate Strategy & Planning. She will continue her role as
Insider Monkey15 Most Profitable Growth Stocks Now
In this article, we will discuss the 15 Most Profitable Growth Stocks Now. You can skip our industry overview and go directly to the 5 Most Profitable Growth Stocks Now. Growth stocks refer to listed companies that are growing their profits, revenue, or cash flow at a rate that exceeds their competitors and beats the overall […]
- GlobeNewswire
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 27, 2023 – Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares. The following transactions were executed under the program from March 20, 2023, to March 24, 2023: No. of sharesAverage price (DKK)Total value (
- GlobeNewswire
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 177,774 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 164,333 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The re
Insider Monkey13 High Growth Pharma Stocks that are Profitable
In this piece, we will take a look at 13 high growth pharma stocks that are profitable. For more stocks, head on over to 5 High Growth Pharma Stocks that are Profitable. One industry that has rapidly evolved with time and impacted millions, if not billions, of lives is the pharmaceutical sector. Within a hundred […]
- GlobeNewswire
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 29, 2023 COPENHAGEN, Denmark; February 23, 2023 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 29, 2023, at 2:00 PM CEST at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy is attached. About G